Medicines advice

Search Filters

Know what you're looking for?

Submission type

British National Formulary - Chapter

Pharmaceutical company

From

To

Advice

Accepted Not recommended Restricted Superseded Withdrawn Interim acceptance

Process

End of life/orphan Ultra orphan

Additional Details

Patient Access Scheme

Advanced Search

SMC ID	Date	Medicine	Submission Type	Indication
SMC2109	13/08/2018	bosutinib (Bosulif)	Non submission	For treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia.
910/13	09/02/2015	bosutinib (Bosulif)	Resubmission	Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

No medicines have been found.